Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

Peter Kuehl, Jiong Zhang, Yvonne Lin et al. · Nature Genetics · 2001 · 2.2K citations

Life Sciences, Genetics, Molecular Biology +17

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Ron H.J. Mathijssen, R J van Alphen, Jaco J. Verweij et al. · PubMed · 2001 · 752 citations · Full text

Medicine, Oncology, Pharmacology +17

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

Lalitha Iyer, Christopher D. King, P. F. Whitington et al. · Journal of Clinical Investigation · 1998 · 680 citations · Full text

Medicine, Oncology, Pharmacology +17

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

E Gupta, Timothy M. Lestingi, Rosemarie Mick et al. · PubMed · 1994 · 506 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

Shinji Mizuarai, Naohiko Aozasa, Hidehito Kotani · International Journal of Cancer · 2003 · 317 citations

Medicine, Oncology, Pharmacology +17